Ugly Market, Beautiful Bargains? 2 Dividend Stocks With Big Upside Potential

Impact · against what's priced in

The article provides no catalyst for Clorox as the market continues to explicitly reject the sales growth targets it highlights. For Hormel Foods, the outlook is marginally positive based on EPS growth targets and the Brakebush acquisition, though these are modest gains.

CLX+0.00: Challenges what's priced in
The price assumes: The company's forecast of 13-14% sales growth for the fiscal year

Ugly Market, Beautiful Bargains? 2 Dividend Stocks With Big Upside Potential

What matters in this story

Jeronimo Martins: Poland's Macro Hangover

Ugly Market, Beautiful Bargains? 2 Dividend Stocks With Big Upside Potential

What matters in this story

Jeronimo Martins: Poland's Macro Hangover

How each ticker is affected

Track these names every morning.

Mousetraps: 7 High-Yield REITs Risking Dividend Cuts

West Pharma: Still A Buy, But Expectations Are Rising

Microsoft Stock Is on Track to Trail the S&P 500 for a 3rd Straight Year. History Says What Happened After Its Last 2 Streaks.

Constellation Brands: Remain A Buy With A Compelling Valuation

Ugly Market, Beautiful Bargains? 2 Dividend Stocks With Big Upside Potential

What matters in this story

Next reads from the same story arc

Jeronimo Martins: Poland's Macro Hangover

Ugly Market, Beautiful Bargains? 2 Dividend Stocks With Big Upside Potential

What matters in this story

Next reads from the same story arc

Jeronimo Martins: Poland's Macro Hangover

How each ticker is affected

Track these names every morning.

Mousetraps: 7 High-Yield REITs Risking Dividend Cuts

West Pharma: Still A Buy, But Expectations Are Rising

Microsoft Stock Is on Track to Trail the S&P 500 for a 3rd Straight Year. History Says What Happened After Its Last 2 Streaks.

Constellation Brands: Remain A Buy With A Compelling Valuation